Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019891 | 0.87 | CNR1 (0.42) | MEN1KMT2ACNR1NAAAALDH1A1 | |
| SCHEMBL19475788 | 0.85 | CASP2 (0.50) | MEN1KMT2ACNR1NAAACASP2 | |
| SCHEMBL25716051 | 0.83 | CASP2 (0.59) | MEN1KMT2ANAAACASP2 | |
| SCHEMBL8429841 | 0.83 | GAA (0.42) | MEN1KMT2ACNR1NAAAPTGS1 | |
| SCHEMBL25122098 | 0.82 | CASP2 (0.62) | MEN1KMT2ANAAACASP2 | |
| SCHEMBL8956580 | 0.82 | MEN1 (0.45) | MEN1KMT2ACNR1NAAACASP2 | |
| SCHEMBL25091538 | 0.82 | CASP2 (0.62) | MEN1KMT2ANAAACASP2 | |
| SCHEMBL8121558 | 0.82 | MEN1 (0.45) | MEN1KMT2ACNR1NAAACASP2 | |
| SCHEMBL2025671 | 0.82 | MEN1 (0.45) | MEN1KMT2ACNR1NAAACASP2 | |
| SCHEMBL18602384 | 0.80 | MCL1 (0.54) | MEN1KMT2ACNR1NAAACASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| CN-101827838-A | Cannabinoid receptor ligand | ASTRAZENECA AB | 2010-09-08 | — | — | CN | disclosed |
| EP-1845106-B1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1845106-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1157040-B1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | MEN1 3055/4885KMT2A 2567/4885CNR1 17/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | MEN1 3215/4885KMT2A 2050/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.